Sana Biotechnology Obtains Exclusive License from National Institutes of Health for CD22 CAR Construct

Sana Biotechnology, Inc. announced that the company entered into an agreement with the National Cancer Institution, an institute of the National Institutes of Health, for worldwide exclusive commercial rights to the NIH’s CD22 CAR with a fully-human binder for use in certain in vivo gene therapy and ex vivo allogeneic CAR T applications for B cell malignancies.